DUBLIN–(BUSINESS WIRE)–The “Confocal Microscopes Market to 2027 – Global Analysis and Forecasts By Type, End User and Geography” report has been added to ResearchAndMarkets.com’s offering. The global confocal microscopes market is expected to reach U…
Author: Business Wire
MYX THERAPEUTIQUES PRÉSENTE À LA 9e CONFÉRENCE ANNUELLE SUR LES OPPORTUNITÉS DE PARTENARIAT EN LIVRAISON DE MÉDICAMENTS (PODD)
MONTRÉAL–(BUSINESS WIRE)–MyX Therapeutics Inc, une compagnie offrant une plateforme unique de livraison ciblant les muqueuses, annonce de nouvelles données provenant d’études précliniques confirmant que sa nouvelle formulation, constituée de nanopart…
Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting
LEXINGTON, Mass.–(BUSINESS WIRE)– #aldeyratherapeutics–Aldeyra Therapeutics will discuss its Phase 3 ocular programs on Thursday, October 10 at the Ophthalmology Innovation Summit in San Francisco.
MyX Therapeutics Presents at the 9th Annual Partnership Opportunities in Drug Delivery (PODD) Conference
MONTREAL–(BUSINESS WIRE)– #MyXdelivery–MyX Therapeutics Inc, a unique enabling mucosal delivery platform company, announces new data from preclinical studies confirming MyX’s mucosal targeting nanoparticle eye drop formulation allows once-a-week dos…
Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting on October 23, 2019
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D.,…
Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Edmonton-Developed VR Technology Brings Innovative Learning to Eye Institute of Alberta’s Eye Ball Gala
EDMONTON, Alberta–(BUSINESS WIRE)–The Eye Institute of Alberta held their second annual Eye Ball Gala on Sept. 28 where innovative Edmonton-developed VR technology was demonstrated.
Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announc…
Humana’s 2020 Medicare Health Plans Demonstrate More Ways to Care for the Whole Person
LOUISVILLE, Ky.–(BUSINESS WIRE)–Humana’s 2020 Medicare health plans demonstrate more ways to care for the whole person.
Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that the product-specific J-code for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros’ commercial drug marketed for use…
Second Sight Announces $2.4 Million, Four-Year Grant from National Institutes of Health to Develop Spatial Localization and Mapping Technology
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision…
UnitedHealthcare’s 2020 Medicare Plans Offer More Ways to Help People Stay Healthy and Save Money
MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare’s 2020 Medicare plans offer more ways to help people stay healthy and save money.
Larkspur Optometry Enters Strategic Partnership With Eyecare Services Partners and Shasta Eye Medical Group
DALLAS–(BUSINESS WIRE)–Eyecare Services Partners Acquires Larkspur Optometry
Ophthalmology Drugs: Global Market Forecasts to 2022 Featuring Novartis, Roche, Allergan, Valeant Pharmaceuticals Intl, Bayer, and More – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Drugs Global Market Forecast To 2022” report has been added to ResearchAndMarkets.com’s offering. Where is the largest and fastest growing market for the ophthalmology drugs? How does the market relate to the…
Stanton Optical, a Leading Eye Health Provider, Opens New Retail Store in Fresno Area Today
CLOVIS, Calif.–(BUSINESS WIRE)– #California–Stanton Optical, a retail brand of Now Optics, which is a leading eye health provider opens a new retail store Clovis, Calif. at 200 W. Shaw Ave.
Stanton Optical, un Proveedor Líder en la Atención de la Vista, Abre Hoy una Nueva Tienda Minorista en el Área de Fresno
CLOVIS, California–(BUSINESS WIRE)–Stanton Optical, una marca minorista de Now Optics, que es un proveedor líder de la atención de la vista que ofrece atención oftalmológica accesible y económica, anunció hoy la inauguración de una nueva tienda minor…
Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing
MALVERN, Pa, & TIANJIN, China–(BUSINESS WIRE)– #Biotechnology–Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing
Lineage Cell Therapeutics to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from …
IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference
NEW YORK–(BUSINESS WIRE)–IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present an overview of the Company at the Chardan Genetic Medicines Conference.
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
MALVERN, Pa.–(BUSINESS WIRE)– #Biotechnology–Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company.